From WebMD · · 1m 20s
FDA approves Atebrioz for rare bone growth disorder
The FDA has approved Atebrioz to treat fibrodysplasia ossificans progressiva, a rare genetic disease where soft tissue gradually turns to bone.
In brief
The FDA has approved Atebrioz to treat fibrodysplasia ossificans progressiva, a rare genetic disease where soft tissue gradually turns to bone. The FDA approved Atebrioz for fibrodysplasia ossificans progressiva, a rare genetic disorder causing abnormal bone growth, based on a trial showing it reduced new bone…
What is fibrodysplasia ossificans progressiva
Fibrodysplasia ossificans progressiva is a very rare genetic disease where soft tissues like muscles, tendons, and ligaments gradually turn into bone. This extra bone limits movement, causes deformities, and leads to severe disability.
FDA approves Atebrioz for FOP patients
The FDA has approved Atebrioz, also called zilurgisertib, for adults and children aged twelve or older with fibrodysplasia ossificans progressiva. The drug works by blocking a bone-growth protein signal to reduce abnormal bone formation.
Trial shows Atebrioz reduced bone growth
In a study of sixty-three patients aged twelve or older, those taking Atebrioz had an average decrease of three point two cubic centimetres in new bone volume after twenty-four weeks.
How to take Atebrioz and key warnings
Atebrioz is a tablet taken once daily by mouth, with or without food.It cannot be taken during pregnancy or while breastfeeding.Common side effects include headaches, joint pain, nosebleeds, nausea, and upper respiratory tract infections.
In short
The FDA approved Atebrioz for fibrodysplasia ossificans progressiva, a rare genetic disorder causing abnormal bone growth, based on a trial showing it reduced new bone formation in patients aged twelve and older.
